Literature DB >> 22761096

Thrombotic events after discontinuing dabigatran: rebound or resumption?

Katie M Thorne, Stephen Dee, Sisira Jayathissa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22761096     DOI: 10.1136/bmj.e4469

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  2 in total

Review 1.  Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.

Authors:  Christina L Fanola
Journal:  Vasc Health Risk Manag       Date:  2015-05-27

2.  Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry.

Authors:  Nina Vene; Alenka Mavri; Mirjam Gubenšek; Gregor Tratar; Tjaša Vižintin Cuderman; Maja Pohar Perme; Aleš Blinc
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.